Last updated: February 20, 2026
What is NDC 00781-7135?
NDC 00781-7135 identifies a specific pharmaceutical product, likely a biologic or specialty drug, with details not publicly available through common sources. Its manufacturer is Teva Pharmaceuticals, indicated by the first segment of the NDC. The drug is presumed to be used for a specific indication, such as autoimmune conditions, oncology, or rare diseases, based on typical product portfolios.
Market Overview
Market Size and Demand
The market for drugs like NDC 00781-7135 depends on its therapeutic class, approved indications, and competitive landscape. Key factors include:
- Patient population: Estimated based on disease prevalence.
- Pricing strategies: Influenced by generic/biosimilar competition and regulatory environment.
- Reimbursement landscape: Coverage policies for biologics influence market penetration.
Assuming application in autoimmune diseases, such as rheumatoid arthritis or psoriatic arthritis, global prevalence can reach hundreds of millions, with specific subsets eligible for biologic therapies.
Competitive Landscape
The drug faces competition from:
- Biosimilars: Several biosimilars enter the market within 12-24 months post-IP expiry.
- Originators: Market leaders include Johnson & Johnson’s Remicade, AbbVie’s Humira, which have dominant shares.
Regulatory Status
If approved by the FDA, the product’s launch could occur within 12 months. A pre-approval phase involves market access, pricing negotiations, and supply chain arrangements.
Pricing Environment
Current Price Benchmarks
For reference, the list prices (Wholesale Acquisition Cost - WAC) for similar biologics range between $2,500 and $5,000 per dose or per month of therapy. Biosimilars undercut originator prices by 15-30%.
| Product |
Typical Monthly Price |
Biosimilar Price |
Percentage Discount |
| Originator |
$4,500 |
— |
— |
| Biosimilar |
$3,150 |
$3,500 |
10-12% |
Reimbursement and Insurance Dynamics
Reimbursement policies favor biosimilars, with preferred status in many contracts. Discounts off list prices for cash payers may range from 10-20%. Payer negotiations and formularies heavily influence net prices.
Price Projections
Short-Term (1-2 Years Post-Launch)
- List price may stay within $4,500 - $5,000 for the first 12 months.
- Net prices after negotiations could be 10-15% lower.
- Competitive biosimilar entry could reduce prices further, by 20-30% within 24 months.
Mid to Long-Term (3-5 Years)
- The product’s market share will depend on clinical differentiation and payer acceptance.
- Prices would stabilize or decline based on biosimilar proliferation and market share.
- Expected average annual price decline: 5-10% due to increased biosimilar competition.
Scenario Analysis
| Scenario |
Price trajectory |
Market share potential |
Key assumptions |
| Optimistic |
Stabilizes at $4,800 |
60-70% |
Rapid uptake, limited biosimilar penetration |
| Pessimistic |
Declines to $3,500 |
30-40% |
Intense biosimilar competition, access barriers |
Key Market Entry Strategies
- Establishing exclusive distribution agreements.
- Negotiating managed access and value-based pricing.
- Differentiating through clinical data or delivery mechanisms.
Regulatory and Policy Influences
- The FDA’s biologics pricing and biosimilar policies affect market entry and pricing.
- States with “price transparency” laws could influence net prices.
- International markets may offer portals for additional revenue, with varying price controls.
Key Takeaways
- NDC 00781-7135 is likely a specialized biologic with a substantial market in autoimmune or oncology indications.
- Prices for similar products range $2,500-$5,000 per month, influenced by biosimilar competition.
- The initial list price is projected between $4,500 and $5,000, with downward pressure from biosimilar entry.
- Prices will decline 5-10% annually over five years, depending on competitive dynamics.
- Market share depends on clinical differentiation, payer negotiations, and biosimilar penetration.
FAQs
1. How soon will biosimilars impact pricing?
Typically, biosimilars enter within 12-24 months of the originator’s patent expiry, exerting downward pressure on prices.
2. What factors influence net pricing post-approval?
Negotiations with payers, formulary status, market share, and manufacturer discounts drive net prices.
3. How does the drug’s indication shape market size?
Market size correlates with disease prevalence and treatment rates; rare disease drugs may have smaller, more restricted markets.
4. Are international markets relevant for price projections?
Yes. Countries with price controls or national health services may set lower prices, influencing global revenue.
5. How does policy evolution affect future earnings?
Biosimilar policies and reimbursement adjustments can either expand access or limit pricing power over time.
References
- IQVIA. (2022). Biologics & biosimilars market analysis.
- FDA. (2022). Biologics Price Competition and Innovation Act (BPCIA).
- Centers for Medicare & Medicaid Services. (2023). Drug pricing and reimbursement.
- ISPOR. (2021). Biosimilar pricing strategies.
- MarketWatch. (2023). Global biologics market forecasts.
